Betterness

Executive Summary

Betterness is a Boston-based biotech company focused on developing innovative therapies for autoimmune and inflammatory diseases. Founded in 2018, the company operates in a high-demand field but has recently pivoted toward digital health with the launch of Bett-i, a fully autonomous, voice-first life coaching system aimed at health and performance. This shift is reflected in the company's latest fundraising: a $2.5M seed round closed in early 2026. While Betterness maintains its immunology R&D pipeline, near-term attention is dominated by the consumer health product, which could generate early revenue but also raises questions about strategic focus. With limited public details on its therapeutic programs and no disclosed clinical milestones, Betterness remains an early-stage, high-risk opportunity. The seed round provides modest runway, but significant capital will be needed to advance drug candidates or scale the coaching platform. Investors should monitor the reception of Bett-i and any updates on the immunology pipeline.

Upcoming Catalysts (preview)

• Q2 2026Commercial launch of Bett-i voice coaching system60% success
• Q4 2026Announcement of preclinical or clinical data for autoimmune therapy20% success
• Q3 2026Potential follow-on financing or partnership for Bett-i40% success